Form 4: PROCEPT BioRobotics Director Frederic Moll Boosts Stake with RSU and Option Grants

PROCEPT BioRobotics Corp Director Frederic Moll reported the acquisition of 1,538 restricted stock units and 2,771 stock options on June 10, 2025, increasing his beneficial ownership in the company.

Summary

• Frederic H. Moll, a Director of PROCEPT BioRobotics Corp (PRCT), acquired 1,538 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 10, 2025.
• Each RSU represents a contingent right to receive one share of Common Stock and vests in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting following the grant date, subject to continued service.
• Mr. Moll also acquired 2,771 stock options with an exercise price of $64.23 on June 10, 2025.
• These stock options vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting following the grant date, subject to continued service, and are set to expire on June 9, 2035.
• Following these transactions, Mr. Moll's direct beneficial ownership stands at 843,159 shares of Common Stock and 2,771 stock options.

Sentiment

Score: 7

Explanation: The acquisition of shares and options by a director, even if through grants, generally indicates alignment of interests and confidence in the company's future, which is a positive signal for investors. There are no negative disclosures.

Positives

• The acquisition of additional equity (RSUs and stock options) by a director can be interpreted as a positive signal of confidence in the company's future performance and strategic direction.
• The increase in beneficial ownership by a key director further aligns management's interests with those of the shareholders.

Future Outlook

The acquired Restricted Stock Units and Stock Options are subject to vesting conditions, requiring continued service through the earlier of the one-year anniversary of the grant date or the date of the next annual meeting following the grant date, indicating a future commitment from the director.

Industry Context

This Form 4 filing reflects an individual director's equity compensation and ownership changes within the medical device or robotics industry, specifically for PROCEPT BioRobotics. It does not provide broader industry trends but indicates ongoing executive compensation practices.

Stakeholder Impact

• Shareholders: The director's increased beneficial ownership aligns his interests with those of shareholders, potentially signaling confidence in the company's future.
• Employees: The vesting conditions for the RSUs and options are tied to continued service, which is a standard incentive mechanism for retaining and motivating key personnel.

Next Steps

• Vesting of 1,538 Restricted Stock Units on the earlier of June 10, 2026, or the date of the next annual meeting, subject to continued service.
• Vesting of 2,771 Stock Options on the earlier of June 10, 2026, or the date of the next annual meeting, subject to continued service.

Key Dates

Recommendation

Keywords

PROCEPT BioRobotics, PRCT, Frederic Moll, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Director, Equity Acquisition, Beneficial Ownership